

IN THE CLAIMS

Please amend the claims as follows:

Claims 1-2 **[Cancelled]**

3. **[Currently Amended]** The A pseudotyped retrovirus virion comprising a Lymphocytic Choriomeningitis Virus (LCMV) strain WE-54 envelope glycoprotein of claim 1, wherein the envelope glycoprotein comprises a phenylalanine at residue 153.

4. **[Currently Amended]** The A pseudotyped retrovirus virion comprising a Lymphocytic Choriomeningitis Virus (LCMV) strain WE-54 envelope glycoprotein of claim 1, wherein the envelope glycoprotein comprises a phenylalanine at residue 260 and a phenylalanine at residue 153.

Claims 5-7 **[Cancelled]**

8. **[Currently Amended]** The A pseudotyped feline immunodeficiency virus (FIV) virion comprising a envelope glycoprotein from Lymphocytic Choriomeningitis Virus (LCMV) strain WE-54 FIV of claim 6, wherein the envelope glycoprotein comprises a phenylalanine at residue 153.

9. **[Currently Amended]** The A pseudotyped feline immunodeficiency virus (FIV) virion comprising a envelope glycoprotein from Lymphocytic Choriomeningitis Virus (LCMV) strain WE-54 FIV of claim 6, wherein the envelope glycoprotein comprises a phenylalanine at residue 260 and a phenylalanine at residue 153.

Claims 10-11 **[Cancelled]**

12. **[Currently Amended]** The An isolated vector comprising a nucleic acid encoding an envelope glycoprotein from Lymphocytic Choriomeningitis Virus (LCMV) strain WE-54 of claim 10, wherein the envelope glycoprotein comprises a phenylalanine at residue 153.

13. **[Currently Amended]** ~~The~~ An isolated vector comprising a nucleic acid encoding an envelope glycoprotein from Lymphocytic Choriomeningitis Virus (LCMV) strain WE-54 of claim 10, wherein the envelope glycoprotein comprises a phenylalanine at residue 260 and a phenylalanine at residue 153.

14. **[Currently Amended]** A method of producing in the form of infectious particles a transgene vector containing a remedial gene, comprising transfecting a cell with

- (a) a packaging vector;
- (b) a vector according to claims 12 or 13 ~~any of claims 10-13~~, and
- (c) a transgene vector comprising the remedial gene and a functional packaging signal,

which by itself is incapable of causing a cell to produce transducing vector particles,

wherein the cell produces infectious transducing vector particles comprising the transgene vector in RNA form, a Gag protein, a Pol protein, and a ~~pseudotyped~~ an envelope glycoprotein from Lymphocytic Choriomeningitis Virus (LCMV) strain WE-54.

Claims 15-19 **[Cancelled]**

20. **[Currently Amended]** ~~The~~ A packaging cell line comprising an inducible expression nucleic acid sequence comprising a polynucleotide encoding an LCMV-WE54 envelope glycoprotein, of claim 18 wherein the envelope glycoprotein comprises a phenylalanine at residue 153.

21. **[Currently Amended]** ~~The~~ A packaging cell line comprising an inducible expression nucleic acid sequence comprising a polynucleotide encoding an LCMV-WE54 envelope glycoprotein, of claim 18 wherein the envelope glycoprotein comprises a phenylalanine at residue 260 and a phenylalanine at residue 153.

22. **[Currently Amended]** The packaging cell of claim 20 ~~18~~, further comprising a transgene vector.

23. **[Currently Amended]** The packaging cell of claim 20 ~~18~~, wherein the transgene vector comprises a remedial gene.

24. **[Currently Amended]** A method of producing in the form of infectious particles a transgene vector containing a remedial gene, comprising transfecting a packaging cell of claim 20 ~~18~~ with

(a) a packaging vector, and

(b) a transgene vector comprising the remedial gene and a functional packaging signal, which by itself is incapable of causing a cell to produce transducing vector particles, wherein the cell produces infectious transducing vector particles comprising the transgene vector in RNA form, a Gag protein, a Pol protein, and a pseudotyped envelope glycoprotein.

25. **[Currently Amended]** A kit comprising a vector according to claim 12 or claim 13 ~~any of claims 10-13~~, and a transgene vector comprising a functional and compatible packaging signal, the transgene vector being incapable by itself of causing a cell transfected by the transgene vector to encapsulate the RNA form of the transgene vector into a retroviral particle comprising an LCMV-WE54 envelope glycoprotein.

26. **[Original]** The kit of claim 25, wherein the LCMV-WE54 envelope glycoprotein comprises a phenylalanine at residue 260 or a phenylalanine at residue 153, or a phenylalanine at both residue 260 and residue 153.

Claims 27-28 **[Cancelled]**